UCERIS(R) (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA
Business Wire - Mon Sep 15, 4:31PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the FDA has granted tentative approval for UCERIS(R) (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.
Nasdaq Sinks As Tesla, Other Highfliers Get Hit
at Investor's Business Daily - Mon Sep 15, 3:31PM CDT
Major averages ended mixed Monday but the Nasdaq continued to sell off into the close. The Nasdaq slumped 1.1%, while the S&P 500 fell less than 0.1% and the Dow bucked the downdraft with a 0.3% gain. Volume ran higher on the Nasdaq but lower on the...
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - Mon Sep 15, 7:50AM CDT
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Stocks Drag Lower Despite Data; Conversant Soars On ADS Buyout
at Investor's Business Daily - Fri Sep 12, 9:37AM CDT
Stocks leaned lower out of the starting gate Friday, despite an early raft of strong economic data. The Nasdaq and the S&P 500 each dimmed 0.4%. The Dow Jones industrial average backed down 0.3%. Volume was mild to lower, up 1% on the NYSE and down...
Salix Pharmaceuticals Shares Up 35.6% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Sep 10, 4:44PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 5 months, Salix Pharmaceuticals has returned 35.64% as of today's recent price of $147.94.
After Yesterday's Decline of 3.16%, Salix Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Sep 10, 4:02PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $147.56 to a high of $153.26. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $151.32 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Four Stock Spotlight Names Near Buy Points
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
Several Stock Spotlight stocks are near correct buy points and might prove profitable trades if the current uptrend can find more traction. The Stock Spotlight's computer-generated screen highlights stocks with strong earnings, strong sales growth...
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Off the Charts
at The Street - Fri Sep 05, 10:31AM CDT
9/04/14: YY Inc. (YY) broke out above our consolidation level, triggering our entry price. Look for follow-through tomorrow.
Salix Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.81%
Comtex SmarTrend(R) - Thu Sep 04, 4:26PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $153.79 to a high of $158.16. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $157.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
45.1% Return Seen to Date on SmarTrend Salix Pharmaceuticals Call (SLXP)
Comtex SmarTrend(R) - Wed Sep 03, 10:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 45.12% as of today's recent price of $158.28.
Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix
PR Newswire - Wed Sep 03, 8:15AM CDT
Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.
Salix Submits Response to XIFAXAN(R) 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
Business Wire - Tue Sep 02, 6:19AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company's supplemental New Drug Application (sNDA) for XIFAXAN(R) 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix's response, the FDA will have six months to issue a response.
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 44.2% (SLXP)
Comtex SmarTrend(R) - Wed Aug 27, 9:37AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 44.18% as of today's recent price of $157.25.
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
After Big Run, Does Chip Designer NXP Have More Left?
at Investor's Business Daily - Tue Aug 26, 4:27PM CDT
Stock Spotlight has been serving up plenty of strong performers in recent weeks -- not surprising, since the market is in a confirmed uptrend. If the stock market has shown us one thing in recent weeks, it's that breakouts from late-stage bases can...
Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma
PR Newswire - Tue Aug 26, 7:50AM CDT
On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at: